These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18523581

  • 21. Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs.
    Belshan M, Park GS, Bilodeau P, Stoltzfus CM, Carpenter S.
    Mol Cell Biol; 2000 May; 20(10):3550-7. PubMed ID: 10779344
    [Abstract] [Full Text] [Related]

  • 22. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
    DeJong ES, Chang CE, Gilson MK, Marino JP.
    Biochemistry; 2003 Jul 08; 42(26):8035-46. PubMed ID: 12834355
    [Abstract] [Full Text] [Related]

  • 23. Specificity of RSG-1.2 peptide binding to RRE-IIB RNA element of HIV-1 over Rev peptide is mainly enthalpic in origin.
    Kumar S, Bose D, Suryawanshi H, Sabharwal H, Mapa K, Maiti S.
    PLoS One; 2011 Jul 08; 6(8):e23300. PubMed ID: 21853108
    [Abstract] [Full Text] [Related]

  • 24. Molecular and biological characterization of equine infectious anemia virus Rev.
    Carpenter S, Dobbs D.
    Curr HIV Res; 2010 Jan 08; 8(1):87-93. PubMed ID: 20210784
    [Abstract] [Full Text] [Related]

  • 25. Binding of trans-dominant mutant Rev protein of human immunodeficiency virus type 1 to the cis-acting Rev-responsive element does not affect the fate of viral mRNA.
    Benko DM, Robinson R, Solomin L, Mellini M, Felber BK, Pavlakis GN.
    New Biol; 1990 Dec 08; 2(12):1111-22. PubMed ID: 2088501
    [Abstract] [Full Text] [Related]

  • 26. Stereospecificity of short Rev-derived peptide interactions with RRE IIB RNA.
    Litovchick A, Rando RR.
    RNA; 2003 Aug 08; 9(8):937-48. PubMed ID: 12869705
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Formation of trans-activation competent HIV-1 Rev:RRE complexes requires the recruitment of multiple protein activation domains.
    Hoffmann D, Schwarck D, Banning C, Brenner M, Mariyanna L, Krepstakies M, Schindler M, Millar DP, Hauber J.
    PLoS One; 2012 Aug 08; 7(6):e38305. PubMed ID: 22675540
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors.
    Luedtke NW, Tor Y.
    Biopolymers; 2003 Sep 08; 70(1):103-19. PubMed ID: 12925996
    [Abstract] [Full Text] [Related]

  • 40. Structural and functional analysis of the visna virus Rev-response element.
    Tiley LS, Cullen BR.
    J Virol; 1992 Jun 08; 66(6):3609-15. PubMed ID: 1316470
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.